ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

LUCENTIS
Miscellaneous ocular agents
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

REMOVE SELECTED | COMPARE SELECTED

Drug Name:

LUCENTIS Rx

Generic Name and Formulations:
Ranibizumab 6mg/mL, 10mg/mL; soln for oph intravitreal inj; preservative-free.

Company:
Genentech, Inc.

e-Prescribe this drug via Surescripts

Therapeutic Use:

Product Resources »
  • Product Information
  • Coupons, Samples & Vouchers
  • Patient Education and Assistance

Indications for LUCENTIS:

Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME).

Adult Dose for LUCENTIS:

Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 0.5mg every 3 months after the first 4 injections if monthly is not feasible (less effective). RVO: 0.5mg once a month (approx. 28 days). DME: 0.3mg once a month (approx. 28 days).

Children's Dose for LUCENTIS:

Not established.

Pharmacological Class:

Recombinant humanized IgG1 kappa isotype monoclonal antibody fragment.

Contraindications:

Ocular or periocular infections.

Warnings/Precautions:

Monitor intraocular pressure prior to and 30 minutes after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy (Cat.C). Nursing mothers.

Adverse Reactions:

Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events.

Generic Availability:

NO

How Supplied:

Single-use vial—1 (w. supplies)